Kymera Therapeutics Price To Book vs. Revenue
KYMR Stock | USD 46.02 0.89 1.90% |
For Kymera Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kymera Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kymera Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kymera Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kymera Therapeutics over time as well as its relative position and ranking within its peers.
Kymera |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kymera Therapeutics. If investors know Kymera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kymera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kymera Therapeutics is measured differently than its book value, which is the value of Kymera that is recorded on the company's balance sheet. Investors also form their own opinion of Kymera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kymera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kymera Therapeutics' market value can be influenced by many factors that don't directly affect Kymera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kymera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kymera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kymera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kymera Therapeutics Revenue vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Kymera Therapeutics's current stock value. Our valuation model uses many indicators to compare Kymera Therapeutics value to that of its competitors to determine the firm's financial worth. Kymera Therapeutics is rated fifth overall in price to book category among its peers. It is considered the number one company in revenue category among its peers totaling about 22,697,395 of Revenue per Price To Book. Comparative valuation analysis is a catch-all technique that is used if you cannot value Kymera Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Kymera Revenue vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Kymera Therapeutics |
| = | 3.46 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Kymera Therapeutics |
| = | 78.59 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Kymera Revenue vs Competition
Kymera Therapeutics is considered the number one company in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 252.78 Million. Kymera Therapeutics totals roughly 78.59 Million in revenue claiming about 31% of equities under Health Care industry.
Kymera Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Kymera Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kymera Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Kymera Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Kymera Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodys own natural protein degradation system. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Kymera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 160 people.
Kymera Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Kymera Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kymera Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kymera Therapeutics' important profitability drivers and their relationship over time.
Use Kymera Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Kymera Therapeutics Pair Trading
Kymera Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Kymera Therapeutics position
In addition to having Kymera Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Machinery Thematic Idea Now
Machinery
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Machinery theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Machinery Theme or any other thematic opportunities.
View All Next | Launch |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.